This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: Peregrine, Arena, Dendreon, NPS Pharma

Back to Arena: Scott writes, "I recommend you quit bashing Arena. The article you put out today is incorrect. The article suggests that people short Arena. This article is not correct. I have called Arena and let them know about your article. Plus you are only negative on this company. Are you shorting? Please don't put out negative stuff on Arena if it isn't true. If I feel you are bashing Arena and you have incorrect information in an article written again I may need to get a lawyer. I recommend you do some dd [sic] on Arena before you put out false information."

Responding to Scott's email would be unfair piling on, so I'll just keep my mouth shut.

George writes, "Just who is paying you to write the blatantly negative articles on Arena Pharmaceuticals? You have repeated some of the pieces ad nauseum [sic] time after time and often just before important news is about to arrive. My guess is your latest two, yes two at one time, a new low, is because Eisai is just about to announce a launch date for Belviq when the DEA finalise [sic] Schedule IV and Arena receive a landmark $65 million payment. Sorry that you will have to report back to your masters eventually that despite all your heroic rear guard actions, their shorting of Arena was totally misguided and they have lost millions."

Bob W. writes, "Just who is paying you to write the blatantly negative articles on Arena Pharmaceuticals? You have repeated some of the pieces ad nauseum [sic] time after time and often just before important news is about to arrive. My guess is your latest two, yes two at one time, a new low, is because Eisai is just about to announce a launch date for Belviq when the DEA finalise [sic] Schedule IV and Arena receive a landmark $65 million payment. Sorry that you will have to report back to your masters eventually that despite all your heroic rear guard actions, their shorting of Arena was totally misguided and they have lost millions."

Huh. George and Bob's emails are identical, even down to the misspelling of "ad nauseam" and "finalize." If I were paranoid, I'd think there was a conspiracy afoot to pump shares of Arena!

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
4 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
DNDN $0.06 -6.02%
NPSP $45.97 0.02%
ARNA $4.44 0.00%
PPHM $1.30 0.00%
VVUS $2.31 0.00%

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs